Latest Precigen News & Updates

See the latest news and media coverage for Precigen. We track all announcements, press releases, and industry mentions in real time, all in one place.

Precigen

Commercial-stage biopharmaceutical company developing precision medicines

precigen.com

Headquarters: Germantown, United States
Founded year: 2020
Company type: Public company
Number of employees: 150–200
Industry: Pharmaceuticals

Last updated Yesterday

Latest news about Precigen

In short: Precigen secured full FDA approval for PAPZIMEOS and achieved first quarterly profitability amid rapid 2026 sales growth.

Company announcements

October 28 Precigen

Precigen announces third quarter 2026 financial results

The company will host a conference call on November 4, 2026, to discuss Q3 2026 financial performance and provide business updates.

September 21 Precigen

Precigen receives FDA platform technology designation for AdenoVerse

The designation accelerates development of future therapies like PRGN-2009 by leveraging existing data and manufacturing efficiencies from PAPZIMEOS.

August 4 Precigen

Precigen reports Q2 2026 financial results amid PAPZIMEOS growth

PAPZIMEOS revenue more than doubled to $53.1M, driving net income of $20.1M and the company's first quarterly profitability.

July 21 Precigen

Precigen to report Q2 2026 financial results and updates

The company will host a conference call on August 4, 2026 at 4:30 PM ET to discuss.

Media coverage

Yesterday MSN

PGEN stock craters 27% after-hours after rival Inovio's rare disease drug receives FDA approval

Recurrent respiratory papillomatosis (RRP) is a rare condition marked by wart-like growths that develop along the respiratory tract, most frequently in the voice box and...

October 14 CGTLive

FDA Approves Precigen’s Recurrent Respiratory Papillomatosis Gene Therapy Papzimeos | CGTlive®

Notably, the FDA granted Papzimeos a full approval, without a requirement for a confirmatory trial.

September 27 AInvest

Precigen's First Quarterly Profit Is Real, but the $2.8 Billion Price Is a Bet on a Platform That Hasn't Earned a Dollar Yet

Precigen's First Quarterly Profit Is Real, but the $2.8 Billion Price Is a Bet on a Platform That Hasn't Earned a Dollar Yet ...

September 21 Grafa

Precigen receives FDA platform designation

Precigen received FDA platform technology designation for AdenoVerse, supporting PAPZIMEOS and future immunotherapy programs.

Never miss news about Precigen

Track Precigen and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Precigen competitors & trending companies

Browse news for competitors to Precigen and other trending companies.